MCID: PRT010
MIFTS: 62

Parathyroid Carcinoma malady

Categories: Genetic diseases, Rare diseases, Cancer diseases, Endocrine diseases

Aliases & Classifications for Parathyroid Carcinoma

About this section

Aliases & Descriptions for Parathyroid Carcinoma:

Name: Parathyroid Carcinoma 52 11 48 54 70 12 50 13
Parathyroid Cancer 48 27 50
Malignant Tumor of Parathyroid Gland 11 68
Parathyroid Gland Adenocarcinoma 11 68
Parathyroid Gland Neoplasm 11 27
Parathyroid Neoplasms 39 68
Malignant Neoplasm of Parathyroid Gland 11
 
Malignant Neoplasm of the Parathyroid 11
Carcinoma of Parathyroid Gland 11
Neoplasm of Parathyroid Gland 11
Parathyroid Gland Cancer 11
Parathyroid Neoplasm 11
Prtc 70

Characteristics:

Orphanet epidemiological data:

54
parathyroid carcinoma:
Prevalence: <1/1000000 (Europe),1-9/1000000 (Europe),<1/1000000 (United States); Age of onset: Adult; Age of death: adult,elderly

HPO:

64
parathyroid carcinoma:
Inheritance: autosomal dominant inheritance, somatic mutation

Classifications:



External Ids:

OMIM52 608266
Disease Ontology11 DOID:1540
ICD1030 C75.0
ICD9CM32 194.1
MeSH39 D010282
Orphanet54 ORPHA143
ICD10 via Orphanet31 C75.0
MedGen37 C0687150

Summaries for Parathyroid Carcinoma

About this section
UniProtKB/Swiss-Prot:70 Parathyroid carcinoma: These cancers characteristically result in more profound clinical manifestations of hyperparathyroidism than do parathyroid adenomas, the most frequent cause of primary hyperparathyroidism. Early en bloc resection of the primary tumor is the only curative treatment.

MalaCards based summary: Parathyroid Carcinoma, also known as parathyroid cancer, is related to parathyroid cancer, childhood and cdc73-related parathyroid carcinoma, and has symptoms including Array, Array and Array. An important gene associated with Parathyroid Carcinoma is CDC73 (Cell Division Cycle 73), and among its related pathways are Development_Hedgehog and PTH signaling pathways in bone and cartilage development and Transcription_Role of VDR in regulation of genes involved in osteoporosis. Affiliated tissues include the parathyroid gl, kidney and bone, and related mouse phenotypes are neoplasm and endocrine/exocrine gland.

Disease Ontology:11 An endocrine gland cancer located in the parathyroid glands located in the neck.

Wikipedia:71 Parathyroid carcinoma is a rare malignant neoplasm resulting in parathyroid adenoma to carcinoma... more...

Description from OMIM:52 608266

Related Diseases for Parathyroid Carcinoma

About this section

Diseases in the Parathyroid Carcinoma family:

Cdc73-Related Parathyroid Carcinoma

Diseases related to Parathyroid Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 91)
idRelated DiseaseScoreTop Affiliating Genes
1parathyroid cancer, childhood11.9
2cdc73-related parathyroid carcinoma11.8
3hyperparathyroidism-jaw tumor syndrome11.2
4hypochondrogenesis10.4CALCA, PTH
5impotence10.4CALCA, PTH
6polyradiculopathy10.4CALCA, PTH
7dyscalculia10.4CALCA, PTH
8testicular brenner tumor10.4CASR, PTH
9hyperparathyroidism10.4
10bacillary angiomatosis10.4CALCA, PTH
11anal buschke-lowenstein tumor10.3CALCA, PTH
12sensory peripheral neuropathy10.3CASR, PTH
13toenail dystrophy, isolated10.3CALCA, PTH
14calpainopathy10.3CALCA, UCHL1
15central nervous system hemangioma10.3CALCA, PTH
16small cell neuroendocrine carcinoma10.3CCND1, CDC73
17physical disorder10.3CALCA, PTH
18bone deterioration disease10.2CALCA, PTH
19lung combined type small cell carcinoma10.2CALCA, RET
20substernal goiter10.2CALCA, LGALS3
21adenoma10.2
22t cell deficiency10.2CASR, PTH
23soft palate cancer10.1RET, UCHL1
24capillariasis10.1CALCA, CASR, PTH
25breast mucoepidermoid carcinoma10.1CASR, PTH
26acquired hyperkeratosis10.1CALCA, CASR, PTH
27parathyroid adenoma10.1
28astrakhan spotted fever10.1CALCA, CASR, PTH
29leukodystrophy10.1CALCA, CASR, PTH
30lung occult large cell carcinoma10.1CALCA, RET
31hyperparathyroidism 310.1CDC73, MEN1
32mediastinitis10.1
33hyperparathyroidism, familial primary10.1CDC73, MEN1
34nonsyndromic congenital nail disorder 210.1RET, UCHL1
35dysgraphia10.1CALCA, CCND1
36pulmonary coin lesion10.1RET, UCHL1
37chronic inflammatory demyelinating polyradiculoneuropathy10.1LGALS3, RET
38polyomavirus allograft nephropathy10.1CCND1, LGALS3
39chronic myelomonocytic leukemia10.1CALCA, PTH
40pearson syndrome10.1CALCA, MEN1
41isolated levocardia10.1CALCA, MEN1
42thyroiditis10.0
43bladder calculus10.0LGALS3, RET
44parathyroid oncocytic adenoma10.0MEN1, PTH
45carcinoma of the vocal tract10.0CALCA, MEN1
46acidophil adenoma10.0MEN1, PTH
47multiple endocrine neoplasia9.9
48mild pre-eclampsia9.9CALCA, CASR, CDC73, PTH
49vestibular gland benign neoplasm9.9MEN1, PTH
50optic papillitis9.8CCND1, MEN1

Comorbidity relations with Parathyroid Carcinoma via Phenotypic Disease Network (PDN):


Hyperparathyroidism

Graphical network of the top 20 diseases related to Parathyroid Carcinoma:



Diseases related to parathyroid carcinoma

Symptoms & Phenotypes for Parathyroid Carcinoma

About this section


Clinical features from OMIM:

608266

Human phenotypes related to Parathyroid Carcinoma:

 54 64 (show all 38)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypercalcemia64 54 Obligate (100%) HP:0003072
2 parathyroid carcinoma64 54 Obligate (100%) HP:0006780
3 primary hyperparathyroidism54 Obligate (100%)
4 hypophosphatemia54 Very frequent (99-80%)
5 hypercalciuria54 Very frequent (99-80%)
6 elevated circulating parathyroid hormone (pth) level54 Very frequent (99-80%)
7 abnormality of the parathyroid morphology54 Very frequent (99-80%)
8 nephrocalcinosis54 Frequent (79-30%)
9 uterine leiomyoma54 Frequent (79-30%)
10 nephrolithiasis54 Frequent (79-30%)
11 osteoporosis54 Frequent (79-30%)
12 hoarse voice54 Frequent (79-30%)
13 weight loss54 Frequent (79-30%)
14 polydipsia54 Frequent (79-30%)
15 dysphagia54 Frequent (79-30%)
16 infantile hypercalcemia54 Frequent (79-30%)
17 fibroma54 Frequent (79-30%)
18 shortened qt interval54 Frequent (79-30%)
19 fatigue54 Frequent (79-30%)
20 renal insufficiency54 Occasional (29-5%)
21 renal cyst54 Occasional (29-5%)
22 chondrocalcinosis54 Occasional (29-5%)
23 muscle weakness54 Occasional (29-5%)
24 pancreatitis54 Occasional (29-5%)
25 nausea and vomiting54 Occasional (29-5%)
26 constipation54 Occasional (29-5%)
27 headache54 Occasional (29-5%)
28 episodic abdominal pain54 Occasional (29-5%)
29 bone pain54 Occasional (29-5%)
30 peptic ulcer54 Occasional (29-5%)
31 renal hamartoma54 Occasional (29-5%)
32 mandibular pain54 Occasional (29-5%)
33 nephroblastoma (wilms tumor)54 Very rare (<4-1%)
34 thyroid carcinoma54 Very rare (<4-1%)
35 pancreatic adenocarcinoma54 Very rare (<4-1%)
36 testicular neoplasm54 Very rare (<4-1%)
37 lipoma54 Very rare (<4-1%)
38 hyperparathyroidism64 HP:0000843

MGI Mouse Phenotypes related to Parathyroid Carcinoma according to GeneCards Suite gene sharing:

41 (show all 12)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020069.0CCND1, LGALS3, MEN1, RET
2MP:00053798.9CASR, CCND1, CDC73, MEN1, PTH, RET
3MP:00107718.8CASR, CCND1, CDC73, LGALS3, UCHL1
4MP:00053678.6CASR, CDC73, LGALS3, RET, UCHL1
5MP:00053788.3CASR, CCND1, CDC73, MEN1, PTH, RET
6MP:00053768.1CASR, CCND1, CDC73, LGALS3, MEN1, PTH
7MP:00053878.0CASR, CCND1, CDC73, LGALS3, MEN1, PTH
8MP:00053977.9CASR, CCND1, CDC73, LGALS3, PTH, RET
9MP:00053817.8CASR, CCND1, CDC73, LGALS3, MEN1, RET
10MP:00053857.8CCND1, CDC73, LGALS3, MEN1, PTH, RET
11MP:00053887.8CCND1, CDC73, LGALS3, RET, UCHL1
12MP:00107687.4CASR, CCND1, CDC73, LGALS3, MEN1, PTH

Drugs & Therapeutics for Parathyroid Carcinoma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Sensipar16 CINACALCET HYDROCHLORIDE Amgen March 2004
FDA Label: Sensipar
Disease/s that Drug Treats:Hyperparathyroidism / Hypercalcemia
Indications and Usage:16 Sensipar is a calcium-sensing receptor agonist indicated for: concentration time curve) is increased in patients with moderate and Secondary Hyperparathyroidism (HPT) in adult patients with chronic severe hepatic impairment. Patients should be closely monitored forkidney disease (CKD) on dialysis. (1.1) serum calcium, serum phosphorus, and iPTH levels throughout Hypercalcemia in adult patients with Parathyroid Carcinoma (PC). (1.2) treatment. (5.3, 8.7) Hypercalcemia in adult patients with primary HPT for whomparathyroidectomy would be indicated on the basis of serum calciumlevels, but who are unable to undergo parathyroidectomy. (1.3)
DrugBank Targets:14 1. Extracellular calcium-sensing receptor
Mechanism of Action:16 
Target: calcium-sensing receptor
Action: increases sensitivity to activation by extracellular calcium
FDA: The calcium-sensing receptor on the surface of the chief cell of the parathyroid gland is the principal regulatorof PTH synthesis and secretion. Cinacalcet, the active ingredient in Sensipar, directly lowers PTH levels byincreasing the sensitivity of the calcium-sensing receptor to extracellular calcium. The reduction in PTH isassociated with a concomitant decrease in serum calcium levels.

Drugs for Parathyroid Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 157)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
BenzocaineapprovedPhase 418921994-09-7, 94-09-72337
Synonyms:
(p-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
4-amino-benzoic acid ethyl ester
4-aminobenzoic acid ethyl ester
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
AE-562/40377256
AI3-02081
AKOS000119763
AR-1H9065
Acetate, Benzocaine
Aethoform
Aethylium paraminobenzoicum
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
BB_SC-0019
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
Baby Anbesol
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
Benzocaine
Benzocaine (USP/INN)
Benzocaine Acetate
Benzocaine Formate
Benzocaine Hydrobromide
Benzocaine Hydrochloride
Benzocaine Methanesulfonate
Benzocaine [INN:BAN]
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
C07527
CAS-94-09-7
CHEBI:116735
CHEMBL278172
CID2337
Caswell No. 430A
Chloraseptic
D001566
D00552
DB01086
Dermoplast
Diet Ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
ETHYL-P-AMINOBENZOATE
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl Aminobenzoate
Ethyl PABA
 
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
Ethyl p-Aminobenzoate
Ethyl p-Aminophenylcarboxylate
Ethyl p-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
Formate, Benzocaine
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, Benzocaine
Hydrochloride, Benzocaine
I05-0204
IDI1_000932
Identhesin
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
MLS001331704
MLS002153970
Methanesulfonate, Benzocaine
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
NINDS_000932
NSC 122792
NSC 41531
NSC41531
NSC4688
Norcain
Norcaine
Norcainum
Oprea1_750694
Oprea1_827402
Ora-jel
Orabase-B
Orthesin
Otocain
Outgro
Parathesin
Parathesin (TN)
Parathesine
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Prestwick_991
SMR000059025
SPBio_000134
SPBio_002844
SPECTRUM1500139
STK043620
Slim Mint Gum
Solarcaine
Solu H
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
Spectrum_000074
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
benzocaine
ethylaminobenzoate-4
h-4-abz-oet
nchembio.182-comp4
p-(Ethoxycarbonyl)aniline
p-Aminobenzoate
p-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
p-Carbethoxyaniline
p-Ethoxycarboxylic Aniline
p-Ethoxycarboxylic aniline
2
Zoledronic acidapprovedPhase 4, Phase 3, Phase 1290118072-93-868740
Synonyms:
(1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
(1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
(1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid
(1-hydroxy-2-imidazol-1-yl-phosphonoethyl)phosphonic acid monohydrate
(1-hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
118072-93-8
2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid
2-(imidazol-1-yl)-1-hydroxyethylidene-1,1-bisphosphonic acid
AC-1092
AC1L2ACJ
AC1Q6RN3
AKOS005145739
Aclasta
Anhydrous Zoledronic Acid
BIDD:GT0292
BIDD:PXR0134
Bio-0112
Bisphosphonate 3
C088658
CGP 42'446
CGP 42446
CGP 42446A
CGP-42'446
CGP-42446
CHEBI:46557
CHEMBL924
CID68740
D08689
DB00399
 
FT-0082657
HMS2089O09
I06-0710
KS-1132
LS-181815
MolPort-002-885-874
MolPort-003-850-890
NCGC00159521-02
NCGC00159521-03
NSC721517
Novartis brand of zoledronic acid
Reclast
Reclast (TN)
S00092
S1314_Selleck
UNII-70HZ18PH24
ZOL
Zol
Zoledronate
Zoledronic Acid Anhydrous
Zoledronic Acid, Anhydrous
Zoledronic acid
Zoledronic acid (INN)
Zoledronic acid [USAN:INN]
Zometa
Zometa (Novartis)
Zometa (TN)
Zometa Concentrate
Zometa, Zomera, Aclasta and Reclast, Zoledronic Acid
[1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid)
3
Betamethasoneapproved, vet_approvedPhase 4183378-44-99782
Synonyms:
.beta.-Methasone
.beta.-Methasone alcohol
1,4-Pregnadiene-3,20-dione-9alpha-fluoro-16 beta-methyl-11 beta,17alpha,21-triol
16beta-Methyl-1,4-pregnadiene-9alpha-fluoro-11beta,17alpha,21-triol-3,20-dione
16β-Methyl-1,4-pregnadiene-9α-fluoro-11β,17α,21-triol-3,20-dione
24024-03-1
34166_FLUKA
34166_RIEDEL
378-44-9
4-08-00-03501 (Beilstein Handbook Reference)
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11-beta,17,21-trihydroxy-16-beta-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11.beta.,17,21-trihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione
9-Fluoro-16.beta.-methylprednisolone
9-Fluoro-16beta-methylprednisolone
9-Fluoro-16β-methylprednisolone
9-alpha-Fluoro-16-beta-methylprednisolone
9.alpha.-Fluoro-16.beta.-methylprednisolone
9alpha-Fluoro-16 beta-methyl-prednisolone
9alpha-Fluoro-16beta-methylprednisolone
9α-Fluoro-16β-methylprednisolone
AC1L1EYE
AC1L1TT4
AC1Q5HJZ
AKOS001582690
AR-1A7284
AR-1H5595
B1837
B7005_SIAL
B7005_SIGMA
B9675_SIAL
BIDD:PXR0047
BPBio1_000533
BRD-A35108200-001-04-7
BRD-K39188321-001-03-9
BRN 3176546
BSPBio_000483
Bebate
Becort
Bedifos
Betacorlan
Betacortril
Betadexamethasone
Betafluorene
Betamamallet
Betametasona
Betametasona [INN-Spanish]
Betametasone
Betametasone [DCIT]
Betamethasone
Betamethasone (JP15/USP/INN)
Betamethasone Base
Betamethasone Valearate
Betamethasone [USAN:BAN:INN:JAN]
Betamethasone [USAN:INN:BAN:JAN]
Betamethasone alcohol
Betamethasone cream
Betamethasonum
Betamethasonum [INN-Latin]
Betamethasonvalerat Mikron
Betamethazone
Betapredol
Betasolon
Betnelan
 
Betsolan
C22H29FO5
CHEBI:3077
CHEMBL632
CID3003
CID9782
CPD000339803
Celestene
Celeston
Celestona
Celestone
Celestone Syrup and Tablets
Celestone, Betadexamethasone, Flubenisolone, Sch-4831, NCS-39470, Betamethasone
Cellestoderm
Cidoten
D00244
D1961
DB00443
Desacort-Beta
EINECS 206-825-4
Flubenisolone
HMS1569I05
HSDB 3015
Hormezon
I06-0121
KST-1A3042
LS-118466
LT00441022
Luxiq
Luxiqo
MLS-0310139.0001
MLS000686794
MLS000859943
MLS001066413
MLS001332616
MLS002153244
Methazon
MolPort-003-845-025
MolPort-007-981-051
NCGC00164401-01
NCGC00164401-02
NSC 39470
NSC-39470
NSC39470
Prestwick0_000362
Prestwick1_000362
Prestwick2_000362
Prestwick3_000362
Prestwick_703
Rinderon
Rinderon (TN)
Rinderon A
S1500_Selleck
SAM002589959
SCH 4831
SCH-4831
SMP1_000043
SMR000058601
SMR000339803
SPBio_002404
UNII-9842X06Q6M
Valisone
Visubeta
ZINC03876136
beta-Methasone
beta-Methasone alcohol
betamethasone
4
Glycerolexperimental, approvedPhase 422356-81-5753
Synonyms:
1,2,3-Trihydroxypropane
1,2,3-propanetriol
1,2,3-trihydroxypropane
Bulbold
Cristal
E 422
Emery 916
Glyceol Opthalgan
Glycerin
Glycerin, anhydrous
Glycerin,anhydrous
Glycerine
Glycerinum
 
Glyceritol
Glycerol
Glycyl alcohol
Glyrol
Glysanin
IFP
Incorporation factor
Mackstat H 66
Monoctanoin component D
Osmoglyn
Pricerine 9091
Propanetriol
RG-S
Trihydroxypropane
Tryhydroxypropane
5
Cholecalciferolapproved, nutraceuticalPhase 4, Phase 3, Phase 285167-97-06221, 10883523, 5280795
Synonyms:
()-Vitamin D3
(+)-Vitamin D3
(+)-vitamin D3
(1S,3Z)-3-[(2e)-2-[(1R,3AR,7as)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol
(3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7e)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3beta,Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(5E,7E)-9,10-Secocholesta-5,7,10-trien-3-ol
(5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol
(5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(5Z,7e)-(3S)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
1406-16-2
25(OH)D
3-beta,Z,7E-9,10-Secocholestr-5,7,10(19)-trien-3-ol
47763_SUPELCO
57651-82-8
67-97-0
7-Dehydrocholesterol activated
7-Dehydrocholesterol, Activated
7-Dehydrocholesterol, irradiated
7-Dehydrocholestrol, activated
8024-19-9
8050-67-7
89193_FLUKA
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3-ol
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3beta-ol
9,10-Secocholesta-5(Z),7(E),10(19)-trien-3(.beta.)-ol
9,10-Secocholesta-5,7,10(19)-trien-3-beta-ol
9,10-Secocholesta-5,7,10(19)-trien-3-ol
9,10-Secocholesta-5,7,10-trien-3-ol
AB1002422
AC-11697
AC1L1ECK
AC1L1M23
AC1LU7IZ
AC1NQXLN
AC1NR2UO
AC1NR2UR
AC1NR2UU
AC1NS4AJ
AC1NSHJX
AC1O5EOF
AC1O7GAV
AC1O7GQ3
AC1O8FEU
AC1O8PWJ
AC1OF2GI
AC1OF2GL
AC1OIEW5
AC1OIEWB
ACon1_001997
Activated 7-dehydrocholesterol
Arachitol
BPBio1_000460
BSPBio_000418
BSPBio_002408
Bio-0845
C05443
C1357_SIAL
C27H44O
C9756_SIGMA
C9774_SIAL
CAS-67-97-0
CC
CCRIS 5813
CCRIS 6286
CHEBI:283119
CHEBI:28940
CHEMBL1042
CHEMBL432780
CID10000117
CID10045875
CID10340013
CID10883523
CID10894379
CID11014566
CID11025493
CID11058152
CID11463269
CID1548921
CID2735
CID5280795
CID5283710
CID5283711
CID5283712
CID5353527
CID5363362
CID6221
CID6432644
CID6604201
CID6604662
CID6708595
CID6713938
CID6992015
CID6992016
CID7067439
CID7067440
CID7251172
CID7251174
CID9821465
Calciol
Cholecalciferol
Cholecalciferol (D3)
Cholecalciferol (JP15/USP)
Cholecalciferol D3
Cholecalciferol [USAN:BAN:JAN]
Cholecalciferol, D3
Cholecalciferolum
 
Colecalciferol
Colecalciferol (INN)
Colecalciferolo
Colecalciferolo [DCIT]
Colecalciferolum
Colecalciferolum [INN-Latin]
Colecalcipherol
D00188
D3-Vicotrat
D3-Vigantol
DB00169
Delsterol
Delta-D
Delta-D (TN)
Deparal
Devaron
DivK1c_006276
Duphafral D3 1000
EINECS 200-673-2
EINECS 215-797-2
EPA Pesticide Chemical Code 202901
Ebivit
FeraCol
Granuvit D3
HMS1569E20
HMS2092M12
HSDB 820
I05-0041
Irradiated 7-dehydrocholesterol
KBio1_001220
KBio2_001643
KBio2_004211
KBio2_006779
KBio3_001628
KBioGR_001602
KBioSS_001643
LMST03020001
LMST03020219
LMST03020220
LMST03020221
LS-1570
LS-825
LT00244775
MEGxm0_000458
Micro-dee
MolPort-001-740-051
MolPort-001-785-972
MolPort-003-666-021
MolPort-004-946-964
NCGC00016301-01
NCGC00017328-01
NCGC00091072-01
NCGC00142511-01
NCGC00159331-02
NCGC00159331-04
NCGC00178668-01
NCGC00179565-01
NCGC00179565-02
NEO Dohyfral D3
NSC 375571
NSC-375571
NSC375571
Oleovitamin D3
Prestwick0_000429
Prestwick1_000429
Prestwick2_000429
Prestwick3_000429
Prestwick_63
Provitamine
Provitina
Quintox
Rampage
Ricketon
SMP1_000068
SPBio_001298
SPBio_002357
SR-05000001559
SR-05000001559-3
ST057172
SpecPlus_000180
Spectrum2_001369
Spectrum3_000764
Spectrum4_001201
Spectrum_001163
TNP00266
Trivitan
UNII-1C6V77QF41
UPCMLD-DP152
UPCMLD-DP152:001
VITAMIN D
VITAMIN D3 POWDER
VITAMIN_D3
Vi-De3
Vi-de-3-hydrosol
VidDe-3-hydrosol
Videkhol
Vigantol
Vigorsan
Vitamin D3
Vitamin D3 emulsifiable
Vitinc Dan-Dee-3
ZINC04474460
ZINC04492874
ZINC04492875
ZINC04492876
ZINC04492878
bmse000507
calciol
cholecalciferol
delta-D
vitamin d-3
6
Ergocalciferolapproved, nutraceuticalPhase 4, Phase 3, Phase 2, Phase 1123250-14-65280793
Synonyms:
'Ergosterol irradiated'
(+)-Vitamin D2
(3-beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10,(19),22-tetraen-3-ol
(3S,5Z,7E,14xi,17alpha,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3beta,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3beta,5Z,7e,22e)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
(5E,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(5Z,7e,22e)-(3S)-9,10-Seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7e,22e)-(3S)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
22-Tetraen 3beta 9,10,Secoergosta-5,7,10(19)-ol
31316-19-5
4-Methylene-3-[2-[tetrahydro-7a-methyl-1-(1,4,5-trimethyl-2-hexenyl)-4(3aH)-indanylidene]ethylidene]-Cyclohexanol
47768_SUPELCO
50-14-6
7489-18-1
7E677DC1-E1C4-4FC5-8F4A-BCE1857F7E87
8017-28-5
9,10,Secoergosta-5,7,10(19),22-tetraen 3.beta.-ol
9,10-Seco(5Z,7E,22E)-5,7,10(19),22-ergostatetraen-3-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3-beta-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3b-ol
95220_FLUKA
95220_SIGMA
AC-1355
AC1L1FIE
AC1NQXLH
AC1NS4DE
AC1NS9GI
AC1NSSVD
AC1NWAM3
AC1O5EDK
AC1O6WAM
ACon1_002187
Activated ergosterol
BPBio1_000418
BSPBio_000380
BSPBio_001974
Buco-D
C05441
C28H44O
CALCIFEROL IN A GELATIN MATRIX
CALCIFEROL, U.S.P.
CHEBI:28934
CHEMBL1536
CID11003810
CID3249
CID5280793
CID5315257
CID5353610
CID5356615
CID5702050
CID6432478
CID6536972
Calciferol
Calciferol (TN)
Calciferol (vitamin D2)
Calciferolum
Calciferon 2
Condacaps
Condocaps
Condol
Crtron
Crystallina
D-Arthin
D-Tracetten
D00187
DB00153
Daral
Davitamon D
Davitin
De-rat concentrate
Decaps
Dee-Osterol
Dee-Ron
Dee-Ronal
Dee-Roual
Deltalin
Deratol
Detalup
Diactol
Divit urto
Doral
Drisdol
Drisdol (TN)
E5750_SIGMA
EINECS 200-014-9
Ercalciol
Ergocalciferol
Ergocalciferol (D2)
Ergocalciferol (JP15/USP)
Ergocalciferol [INN:BAN:JAN]
Ergocalciferol oil
Ergocalciferol: Vitamin D
 
Ergocalciferolo
Ergocalciferolo [DCIT]
Ergocalciferols
Ergocalciferolum
Ergocalciferolum [INN-Latin]
Ergorone
Ergosterol activated
Ergosterol irradiated
Ergosterol, irradiated
Ertron
Fortodyl
Geltabs
Geltabs Vitamin D
HMS1920K20
HMS2091B19
HMS502I07
HSDB 819
Haliver
Hi-Deratol
Hyperkil
I05-0022
IDI1_000805
Infron
Irradiated ergosta-5,7,22-trien-3-beta-ol
Irradiated ergosta-5,7,22-trien-3.beta.-ol
Irradiated ergosta-5,7,22-trien-3beta-ol
Irradiated ergosterol
LMST03010001
LMST03010014
LS-3228
MEGxm0_000466
MLS001332467
MLS001332468
Metadee
Mina D2
MolPort-001-740-057
MolPort-001-793-930
MolPort-002-526-645
MolPort-003-666-178
MolPort-006-822-629
Mulsiferol
Mykostin
NCGC00142497-01
NCGC00179579-01
NCGC00179579-02
NSC 62792
NSC62792
Novovitamin-D
Oleovitamin D
Oleovitamin D, Synthetic
Oleovitamin D2
Osteil
Ostelin
Prestwick3_000420
Prestwick_554
Radiostol
Radstein
Radsterin
Rodine C
Rodinec
SMR000857106
SPECTRUM1500276
ST057150
STOCK1N-53397
Shock-ferol
Shock-ferol sterogyl
Sorex C.R
Sorex C.R.
Spectrum5_000666
Sterogyl
Synthetic Vitamin D
UNII-VS041H42XC
Uvesterol D
Uvesterol-D
VITAMIN D2
VITAMIN D2 WATER DISPERSABLE U.S.P.
VITAMIN_D2
Vigantol
Vio D
Vio-D
Viostdrol
Viosterol
Viosterol in Oil
Vitamin D2
Vitamin- D2
Vitamin-?D2
Vitamina D2
Vitavel-D
WLN: L56 FYTJ A1 BY1&1U1Y1&Y1&1 FU2U- BL6YYTJ AU1 DQ
ZINC04474571
ZINC04629876
beta-Ol
bmse000510
component of Geltabs Vitamin D
delta-Arthin
delta-Tracetten
ergocalciferol
vitamin d-2
7tannic acidapproved, NutraceuticalPhase 41892
8
Calcitriolapproved, nutraceuticalPhase 4, Phase 3, Phase 220132222-06-3134070, 5280453
Synonyms:
(1R,3S)-5-{2-[(1R,3aS,7aR)-1-((R)-5-Hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexane-1,3-diol
(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
(1S,3R,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(1S,3R,5Z,7E)-9,10-secocholesta-5,7,10-triene-1,3,25-triol
(1S,3R,5Z,7e)-9,10-Secocholesta-5,7,10-triene-1,3,25-triol
(1alpha,3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(1alpha,3beta,5Z,7e)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol
(3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trienetriol
(5Z,7E)-(1S,3R)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1-alpha,3-beta,25-triol
(5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1alpha,3beta,25-triol
(5Z,7e)-(1S,3R)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol
1 alpha,25-Dihydroxyvitamin D3
1,25 (OH)2 D3
1,25 Dihydroxycholecalciferol
1,25(OH)2-20epi-D3
1,25(OH)2D3 & CD4
1,25(OH2)D3
1,25-(OH)2-D3
1,25-(OH)2D3
1,25-DHCC
1,25-DIHYDROXYCHOLECALCIFEROL
1,25-Dihydroxycholecalciferol
1,25-Dihydroxycholecaliferol
1,25-Dihydroxyvitamin D
1,25-Dihydroxyvitamin D3
1,25-dihydroxy vitamin D3
1,25-dihydroxy-20-epi-Vitamin D3
1,25-dihydroxycholecalciferol
1,25D3
1-alpha,-1,25-Dihydroxyvitamin D3
1-alpha,25-Dihydroxycholecalciferol
1-alpha,25-Dihydroxyvitamin D3
1-alpha-25-Dihydroxyvitamin D3
1-alpha-25-dihydroxyvitamin D3
1.Alpha.,25-Dihydroxy-26,27-hexadeuterovitamin D3
17936_FLUKA
17936_SIGMA
1a,25-(OH)2D3
1a,25-Dihydroxycholecalciferol
1a,25-Dihydroxyvitamin D3
1alpha,25(OH)2-D3
1alpha,25(OH)2D3
1alpha,25-Dihydroxycholecalciferol
1alpha,25-Dihydroxyvitamin D
1alpha,25-Dihydroxyvitamin D3
1db1
1α,25(OH)2D3
1α,25-dihydroxycholecalciferol
1α,25-dihydroxyvitamin D3
20-epi-1alpha,25-dihydroxycholecaliferol
25-Dihydroxycholecalciferol
32222-06-3
5-{2-[1-(5-hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexane-1,3-diol
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatriene-1alpha,3beta,25-triol
9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, (1.alpha.,3.beta,.5Z,7E)- & CD4
9,10-seco(5Z,7E)-5,7,10(19)-cholestatriene-1alpha, 3beta, 25-triol
AC-1859
AC1NQX1S
 
Ambap32222-06-3
Asentar
BCBcMAP01_000160
BML2-E03
BSPBio_001287
C01673
CCRIS 5522
CD-2027
CHEBI:17823
CHEMBL846
CID5280453
CPD000466393
Calcijex
Calcijex, Silkis, Rocaltrol, Topitriol, Cholecalciferol,Calcitriol
Calcitriol
Calcitriol (JAN/USAN/INN)
Calcitriol [USAN:INN:BAN:JAN]
Calcitriolum
Calcitriolum [INN-Latin]
D00129
D1530_SIGMA
DN 101
DN-101
Decostriol
Dihydroxyvitamin D3
EINECS 250-963-8
HMS1361A09
HMS1791A09
HMS1989A09
HMS2051F06
HMS2089N03
HSDB 3482
IDI1_033757
LMST03020258
LS-53093
MC-1288
MC1288
MLS000759536
MLS001424122
MolPort-002-045-698
NCGC00161327-01
NCGC00161327-04
Ro 21-5535
Ro 215535
Ro-21-5535
Rocaltrol
Rocaltrol (TN)
S1466_Selleck
SAM001246772
SMR000466393
Silkis
Soltriol
Spectrum5_002061
Topitriol
Toptriol
U 49562
Vectical
ZINC03924790
calcitriol
vit D
9
Alfacalcidolapproved, nutraceuticalPhase 45241294-56-85282181
Synonyms:
(5Z,7e)-9,10-Seco-5,7,10(19)-cholestatrien-1alpha,3beta-diol
1-Hydroxycholecalciferol
1-hydroxycholecalciferol
1alpha-Hydroxy-vitamin D3
 
1alpha-hydroxycholecalciferol
1alpha-hydroxyvitamin D3
9,10-Secocholesta-5,7,10(19)-triene-1alpha,3beta-diol
Alfacalcidolum
Alsiodol
10
Vitamin Aapproved, nutraceutical, vet_approvedPhase 446811103-57-4, 68-26-8445354
Synonyms:
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-ol
(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
.alpha.lin
.alpha.sterol
.beta.-Retinol
11103-57-4
13123-33-6
1341-18-0
1406-67-3
17104-91-5
1rbp
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclchexen-1-yl)-2,4,6,8-nonatetraen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonate-traen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraen-1-ol
3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-E)-Isomer
4-06-00-04133 (Beilstein Handbook Reference)
53637-36-8
5979-23-7
68-26-8
95144_FLUKA
95144_SIGMA
95146_FLUKA
95146_SIGMA
A-Mulsal
A-Sol
A-Vi-Pel
A-Vitan
AC-11701
AC1L9HU3
AC1Q7BU9
ACON
ALL-TRANS RETINOL (SEE ALSO RETINOID PROJECT 1)
AR-1L3057
ATAV
Afaxin
Agiolan
Agoncal
Alcohol 9,13-dimethyl-7-(1,1,5-trimethyl-6-cyclohexen-5-yl)-7,9,11,13-nonatetraen-15-ol
Alcovit A
All Trans Retinol
All-trans retinol
All-trans-Retinol
Alphalin
Alphasterol
Anatola
Anatola A
Anti-infective vitamin
Antixerophthalmic vitamin
Antixerophthalmisches Vitamin
Aoral
Apexol
Apostavit
Aquasol A Parenteral
Aquasynth
Atars
Avibon
Avita
Avitol
Axerol
Axerophthol
Axerophtholum
BIDD:PXR0102
BRN 0403040
Bentavit A
Biosterol
C00473
C17276
C20H30O
CCRIS 5444
CHEBI:17336
CHEMBL986
CID445354
Chocola A
Cylasphere
D014801
D06543
DB00162
Del-VI-A
Disatabs Tabs
Dofsol
Dohyfral A
EINECS 200-683-7
EINECS 234-328-2
Epiteliol
HMS1921B04
HMS2092L13
HMS501I08
HSDB 815
Hi-A-Vita
Homagenets Aoral
Homagenets aorl
Hydrovit A
IDI1_000486
LMPR01090001
LPK
LS-1578
Lard Factor
M.V.C. 9+3
M.V.I.-12
 
MLS001066379
MLS001074751
MolPort-001-785-962
Mvc Plus
Myvpack
NCGC00091784-01
NCGC00091784-02
NCGC00091784-03
NCGC00091784-04
NCGC00091784-05
NCGC00091784-06
NSC 122759
NSC122759
Nio-A-Let
Oleovitamin A
Ophthalamin
Plivit A
Prepalin
R7632_SIGMA
Retin-11,12-t2-ol (9CI)
Retinol
Retinol [INN:BAN]
Retinol solution
Retinol, all-trans- (8CI)
Retinol-(cellular-retinol-binding-protein)
Retinolo
Retinolo [DCIT]
Retinolum
Retinolum [INN-Latin]
Retrovitamin A
Ro-a-vit
Rovimix A 500
SDCCGMLS-0066724.P001
SMP2_000102
SMR000112036
SPECTRUM1501203
ST057232
Sehkraft A
Solu-A
Spectrum5_000993
Spectrum5_001997
Super A
Testavol
Testavol S
Thalasphere
UNII-81G40H8B0T
UNII-G2SH0XKK91
Vaflol
Vafol
Veroftal
Vi-.alpha.
Vi-Alpha
Vi-Dom-A
Vi-a
Vio-A
Vitamin A
Vitamin A (Feed)
Vitamin A (USP)
Vitamin A alcohol
Vitamin A alcohol (VAN)
Vitamin A cryst
Vitamin A1
Vitamin A1 alcohol
Vitamin A1 alcohol, all trans
Vitamin- A
Vitamin- A alcohol
Vitamin- A alcohol solution
Vitamin- A1
Vitamin-?A
Vitamin-?A alcohol
Vitamin-?A alcohol solution
Vitamin-?A1
Vitamine A
Vitaminum A
Vitavel A
Vitavel-A
Vitpex
Vogan
Vogan-Neu
Vogan-nu
WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U2Q C1 C1
Wachstumsvitamin
ZINC03831417
Zinosan N
[11,12-3H]-Retinol
alin
all-trans-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
all-trans-Retinol
all-trans-Retinyl alcohol
all-trans-Vitamin A
all-trans-Vitamin A alcohol
all-trans-Vitamin A1
all-trans-retinol
all-trans-retinyl alcohol
all-trans-vitamin A alcohol
b-Retinol
beta-Retinol
retinol
tROL
trans-Retinol
trans-Retinol acid (Vitamin A)
trans-Vitamin A alcohol
trans-retinol
11Calcium, DietaryPhase 4, Phase 3, Phase 2, Phase 15525
12Cinacalcet HydrochloridePhase 4, Phase 2, Phase 3, Phase 169
13Pharmaceutical SolutionsPhase 4, Phase 2, Phase 37793
14Bone Density Conservation AgentsPhase 4, Phase 3, Phase 2, Phase 13266
15Calcimimetic AgentsPhase 4, Phase 2, Phase 3, Phase 169
16ErgocalciferolsPhase 4, Phase 3, Phase 2, Phase 11232
17VitaminsPhase 4, Phase 2, Phase 3, Phase 15095
18HormonesPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 113979
19MicronutrientsPhase 4, Phase 3, Phase 2, Phase 15802
20Trace ElementsPhase 4, Phase 3, Phase 2, Phase 15802
21Hormone AntagonistsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 112778
22vitamin dPhase 4, Phase 2, Phase 3, Phase 11653
23Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 112767
24Retinol palmitatePhase 4468
25CalcifediolPhase 4, Phase 3, Phase 14219356-17-3
26HematinicsPhase 4, Phase 21630
27DiphosphonatesPhase 4, Phase 3, Phase 2446
28Vasoconstrictor AgentsPhase 4, Phase 3, Phase 22027
291 alpha-hydroxyergocalciferolPhase 4, Phase 3, Phase 125
30
s 1 (combination)Phase 4, Phase 2364
Synonyms:
 
Gimeracil / oteracil / tegafur
TS 1
31HydroxycholecalciferolsPhase 4, Phase 3102
32Respiratory System AgentsPhase 44818
33AnticoagulantsPhase 42516
34Ferric CompoundsPhase 4184
35glucocorticoidsPhase 44920
36Chelating AgentsPhase 41365
37Betamethasone sodium phosphatePhase 4183
38Betamethasone acetatePhase 47
39Anti-Inflammatory AgentsPhase 410355
40Betamethasone-17,21-dipropionatePhase 4183
41Betamethasone benzoatePhase 4183
42Anti-Asthmatic AgentsPhase 43369
43Betamethasone ValeratePhase 41832152-44-5
44HepcidinsPhase 453
45Vitamin D2NutraceuticalPhase 4, Phase 3, Phase 2, Phase 11232
46CalciferolNutraceuticalPhase 4, Phase 3, Phase 2, Phase 11334
47retinolNutraceuticalPhase 4468
48
Citric Acidnutraceutical, vet_approvedPhase 4110677-92-9311
Synonyms:
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Aciletten
Anhydrous citrate
Anhydrous citric acid
Chemfill
Citraclean
 
Citrate
Citretten
Citric acid
Citro
Citronensäure
E 330
Hydrocerol A
Kyselina citronova
Suby G
Uro-trainer
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
49CitrateNutraceuticalPhase 41106
50OliveNutraceuticalPhase 4258

Interventional clinical trials:

(show top 50)    (show all 172)
idNameStatusNCT IDPhase
1Cinacalcet in Management of Secondary Hyperparathyroidism in Haemodialysis PatientsUnknown statusNCT02338934Phase 4
2A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid CancerCompletedNCT00037518Phase 4
3Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone MetastasesCompletedNCT00219219Phase 4
4Initial Dosing of Paricalcitol in Secondary HyperparathyroidismCompletedNCT00307840Phase 4
5Compare the Efficacy of Cinacalcet vs Traditional Vitamin D for Secondary Hyperparathyroidism (SHPT) Among Subjects Undergoing HemodialysisCompletedNCT01181531Phase 4
6Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH LevelCompletedNCT01101113Phase 4
7ACHIEVE: Optimizing the Treatment of Secondary HyperparathyroidismCompletedNCT00135304Phase 4
8Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary HyperparathyroidismCompletedNCT01115543Phase 4
9Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin DCompletedNCT00977080Phase 4
10Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial DoseCompletedNCT00891813Phase 4
11START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary HyperparathyroidismCompletedNCT00132431Phase 4
12Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary HyperparathyroidismCompletedNCT00123461Phase 4
13Vitamin D Deficiency in Chronic Kidney Disease (CKD) PatientsCompletedNCT00958451Phase 4
14Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal TransplantationCompletedNCT01178450Phase 4
15Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on DialysisCompletedNCT00537979Phase 4
16A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® InjectionCompletedNCT00463021Phase 4
17Vitamin D Effects in Overweight PatientsCompletedNCT00493012Phase 4
18Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT)CompletedNCT00823303Phase 4
1920070360 Incident DialysisCompletedNCT00803712Phase 4
20Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in HypoparathyroidismRecruitingNCT02910466Phase 4
21Steroids in the Postoperative Transient Hypoparathyroidism Total ThyroidectomyRecruitingNCT02652884Phase 4
22A Study of Ferric Citrate to Improve Inflammation and Lipid LevelsRecruitingNCT02661295Phase 4
23Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.Active, not recruitingNCT01939977Phase 4
24Intravenous Paricalcitol in Chronic Hemodialysis PatientsActive, not recruitingNCT03023748Phase 4
25Cholecalciferol Supplementation for Anemia and Mineral and Bone Disorder in Hemodialysis PatientsActive, not recruitingNCT02214563Phase 4
26Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis SubjectsTerminatedNCT00664430Phase 4
27Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving HemodialysisTerminatedNCT00446329Phase 4
28Cinacalcet in Paediatric Secondary Hyperparathyroidism (SHPT) Due to Chronic Kidney Disease (CKD)Unknown statusNCT01479088Phase 2, Phase 3
29An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary HyperparathyroidismCompletedNCT01460030Phase 3
30Cinacalcet to Treat Familial Primary HyperparathyroidismCompletedNCT00325104Phase 3
31The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone LossCompletedNCT00375505Phase 3
32A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on DialysisCompletedNCT00042653Phase 3
33Assess Impact on Calcium Levels When Hemodialysis Subjects With SHPT Switch From Cinacalcet HCl to AMG 416CompletedNCT01932970Phase 3
34Vitamin D Status of Pregnant Women and Their Children in Eau Claire, South CarolinaCompletedNCT00412087Phase 3
35Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary HyperparathyroidismCompletedNCT01341782Phase 3
36Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D InsufficiencyCompletedNCT01704079Phase 3
37Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D InsufficiencyCompletedNCT01651000Phase 3
38Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002CompletedNCT02282813Phase 3
39Calcium and Vitamin D Malnutrition in Elderly WomenCompletedNCT00352170Phase 3
40Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)CompletedNCT01219855Phase 2, Phase 3
41A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis PatientsCompletedNCT00037635Phase 3
4220120231: Single-arm Extension Study of AMG 416 in the Treatment of SHPT in CKD Subjects on HDCompletedNCT01785875Phase 3
4320120230: Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease on HemodialysisCompletedNCT01788046Phase 3
4420120229: Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease on HemodialysisCompletedNCT01785849Phase 3
45Head-to-Head Study of Etelcalcetide (AMG 416) and CinacalcetCompletedNCT01896232Phase 3
46SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary HyperparathyroidismCompletedNCT00117052Phase 3
47The Effect of Vitamin D Supplementation Among Overweight Jordanian Women With Polycystic Ovary Syndrome (PCOS)CompletedNCT02328404Phase 3
48Phase 3 Study of KHK7580RecruitingNCT02549417Phase 3
49Phase 3 Study of KHK7580RecruitingNCT02549391Phase 2, Phase 3
50Phase 3 Study of KHK7580RecruitingNCT02549404Phase 3

Search NIH Clinical Center for Parathyroid Carcinoma


Cochrane evidence based reviews: parathyroid neoplasms

Genetic Tests for Parathyroid Carcinoma

About this section

Genetic tests related to Parathyroid Carcinoma:

id Genetic test Affiliating Genes
1 Parathyroid Carcinoma27
2 Neoplasm of the Parathyroid Gland27

Anatomical Context for Parathyroid Carcinoma

About this section

MalaCards organs/tissues related to Parathyroid Carcinoma:

36
Kidney, Bone, Thyroid, Prostate, Lung, Lymph node, Brain

FMA organs/tissues related to Parathyroid Carcinoma:

17
The parathyroid gl

Publications for Parathyroid Carcinoma

About this section

Articles related to Parathyroid Carcinoma:

(show top 50)    (show all 514)
idTitleAuthorsYear
1
Denosumab as a long-term palliative therapy in parathyroid carcinoma. (28011854)
2017
2
Denosumab is a long-term option for the management of parathyroid carcinoma-related refractory hypercalcemia. (28011856)
2017
3
18F-FDG PET/CT Osteometabolic Activity in Metastatic Parathyroid Carcinoma. (27276208)
2016
4
Response to "Is denosumab a long-term option for the treatment of parathyroid carcinoma?". (26803152)
2016
5
Recurrence of Hyperparathyroid Hypercalcemia in a Patient With the HRPT-2 Mutation and a Previous Parathyroid Carcinoma in Hyperparathyroidism-Jaw Tumor Syndrome. (27679651)
2016
6
Parathyroid carcinoma. (26771263)
2016
7
Multiple brown tumours from parathyroid carcinoma. (27358103)
2016
8
Ossification of the cervical ligamentum flavum and osseous brown tumor: late manifestations of primary hyperparathyroidism misdiagnosed in a case of parathyroid carcinoma. (27252748)
2016
9
Intrathyroidal oxyphilic parathyroid carcinoma: A potential diagnostic caveat in cytology? (27229757)
2016
10
Parathyroid carcinoma in tertiary hyperparathyroidism. (27664600)
2016
11
Parathyroid Carcinoma and Atypical Parathyroid Neoplasms in MEN1 Patients; A Clinico-Pathologic Challenge. The MD Anderson Case Series and Review of the Literature. (27212590)
2016
12
A germline mutation of HRPT2/CDC73 (70 G>T) in an adolescent female with parathyroid carcinoma: first case report and a review of the literature. (27544721)
2016
13
Is denosumab a long-term option for the treatment of parathyroid carcinoma? (26803154)
2016
14
Diagnostic performance of parafibromin immunohistochemical staining for sporadic parathyroid carcinoma: a meta-analysis. (27250989)
2016
15
Differentiation of parathyroid carcinoma and adenoma by preoperative ultrasonography. (27609904)
2016
16
A case of parathyroid carcinoma accompanied by a brown tumor. (27278852)
2016
17
Pathologic Fracture of the Femur in Brown Tumor Induced in Parathyroid Carcinoma: A Case Report. (27777921)
2016
18
Difficult management in parathyroid carcinoma with synchronous parathyroid hyperplasia. (27677089)
2016
19
Somatic HRPT2 Mutation (Arg234X) of Parathyroid Carcinoma Associated with Slipped Capital Femoral Epiphysis: A First Case Report. (27266237)
2016
20
Intrathyroidal parathyroid carcinoma. A case report and review of literature. (26588997)
2016
21
Oncologic progress for the treatment of parathyroid carcinoma is needed. (27753088)
2016
22
Parathyroid carcinoma with contralateral subcutaneous and breast recurrences: A rare presentation. (26685878)
2016
23
An unusual mediastinal parathyroid carcinoma coproducing PTH and PTHrP: A case report. (27313750)
2016
24
Update on parathyroid carcinoma. (27001435)
2016
25
Controversies in the management of parathyroid carcinoma: A case series and review of the literature. (26708847)
2016
26
Parathyroid carcinoma presenting as mandibular ulceration. (26895764)
2016
27
More Extensive Surgery May Not Improve Survival Over Parathyroidectomy Alone in Parathyroid Carcinoma. (27177488)
2016
28
Association of parathyroid carcinoma and thyroid disorders: A clinical review. (27744598)
2016
29
Preoperative diagnosis and prognosis in 40 Parathyroid Carcinoma Patients. (26939543)
2016
30
Parathyroid carcinoma: Diagnostic criteria, classification, evaluation. (25916757)
2015
31
Parathyroid Carcinoma: Is It Time for Change? (26100817)
2015
32
Pulmonary Embolism and Subclavian Vein Thrombosis in a Patient with Parathyroid Carcinoma: Case Report and Review of Literature. (26591405)
2015
33
Parathyroid Carcinoma: Diagnosis and Clinical Implications. (26177319)
2015
34
Parathyroid Carcinoma: An Update on Treatment Outcomes and Prognostic Factors from the National Cancer Data Base (NCDB). (26077914)
2015
35
Clinicopathological phenotype of parathyroid carcinoma. Therapeutic and prognostic aftermaths. (25800319)
2015
36
Brain metastases of parathyroid carcinoma: Review of the literature and a case report. (25690525)
2015
37
(18)Fluorocholine PET/CT in parathyroid carcinoma: a new tool for disease staging? (26253272)
2015
38
Establishment and characterization of a human parathyroid carcinoma derived cell line. (25655355)
2015
39
A Rare Constellation of HA1rthle Cell Thyroid Carcinoma and Parathyroid Carcinoma. (26813941)
2015
40
Is local resection sufficient for parathyroid carcinoma? (26017790)
2015
41
Non-functional parathyroid carcinoma: a case report and review of the literature. (26408508)
2015
42
The Emerging Role of Denosumab in the Long Term Management of Parathyroid Carcinoma-Related Refractory Hypercalcemia. (25667369)
2015
43
Whole-exome sequencing studies of parathyroid carcinomas reveal novel PRUNE2 mutations, distinctive mutational spectra related to APOBEC-catalyzed DNA mutagenesis and mutational enrichment in kinases associated with cell migration and invasion. (25387265)
2015
44
Parathyroid carcinoma: Challenges in diagnosis and treatment. (25910997)
2015
45
Parathyroid carcinoma: A report of six cases with a brief review of the literature. (26788136)
2015
46
Brown Tumors Due to Primary Hyperparathyroidism in a Patient with Parathyroid Carcinoma Mimicking Skeletal Metastases on (18)F-FDG PET/CT. (26854155)
2015
47
Parathyroid Carcinoma in a 10 Years Old Female Child. (26329966)
2015
48
Comment on: Is central lymph node dissection necessary for parathyroid carcinoma? (25921717)
2015
49
A nonfunctioning parathyroid carcinoma misdiagnosed as a follicular thyroid nodule. (26350418)
2015
50
Parathyroid Carcinoma: A Case Report and Review of the Literature. (26426192)
2015

Variations for Parathyroid Carcinoma

About this section

Clinvar genetic disease variations for Parathyroid Carcinoma:

5
id Gene Variation Type Significance SNP ID Assembly Location
1CDC73NM_024529.4(CDC73): c.766_767delGT (p.Val256Lysfs)deletionPathogenicrs80356650GRCh37Chr 1, 193117033: 193117034
2CDC73NM_024529.4(CDC73): c.687_688dupAG (p.Val230Glufs)duplicationPathogenicrs878855090GRCh38Chr 1, 193142024: 193142025
3CDC73NM_024529.4(CDC73): c.679_680insAG (p.Arg227Lysfs)insertionPathogenicrs80356649GRCh37Chr 1, 193111146: 193111147
4CDC73NM_024529.4(CDC73): c.128G> A (p.Trp43Ter)SNVPathogenicrs121434263GRCh37Chr 1, 193091458: 193091458
5CDC73NM_024529.4(CDC73): c.162C> G (p.Tyr54Ter)SNVPathogenicrs121434265GRCh37Chr 1, 193094272: 193094272
6CDC73CDC73, 1-BP INS, 373AinsertionPathogenicChr na, -1: -1
7CDC73CDC73, 4-BP DEL, 685AGAGdeletionPathogenicChr na, -1: -1
8CDC73NM_024529.4(CDC73): c.85delG (p.Glu29Serfs)deletionPathogenicrs587776560GRCh37Chr 1, 193091415: 193091415
9CDC73NM_024529.4(CDC73): c.13_30del18 (p.Leu5_Gln10del)deletionPathogenicrs587776561GRCh37Chr 1, 193091343: 193091360

Expression for genes affiliated with Parathyroid Carcinoma

About this section
Search GEO for disease gene expression data for Parathyroid Carcinoma.

Pathways for genes affiliated with Parathyroid Carcinoma

About this section

Pathways related to Parathyroid Carcinoma according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.7CCND1, PTH
29.6CALCA, PTH
39.5CCND1, RET
48.8CALCA, RET, UCHL1

GO Terms for genes affiliated with Parathyroid Carcinoma

About this section

Cellular components related to Parathyroid Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1axonGO:00304248.8CALCA, RET, UCHL1

Biological processes related to Parathyroid Carcinoma according to GeneCards Suite gene sharing:

(show all 8)
idNameGO IDScoreTop Affiliating Genes
1beta-catenin-TCF complex assemblyGO:190483710.4CDC73, MEN1
2negative regulation of epithelial cell proliferationGO:005068010.4CDC73, MEN1
3adenylate cyclase-activating G-protein coupled receptor signaling pathwayGO:000718910.3CALCA, PTH
4positive regulation of ossificationGO:00457789.9CALCA, PTH
5cellular calcium ion homeostasisGO:00068749.9CALCA, CASR, PTH
6monocyte chemotaxisGO:00025489.8CALCA, LGALS3
7response to painGO:00482659.4CALCA, RET
8negative regulation of transcription from RNA polymerase II promoterGO:00001229.3CCND1, CDC73, MEN1, PTH

Sources for Parathyroid Carcinoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet